Directions and Challenges in Smoking Cessation Treatment

• Main Author: Jae Yeol Kim
• Format: Article
• Language: English
• Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2020-12-01
• Series: Tuberculosis and Respiratory Diseases
• Subjects: smoking cessation; e-cigarette; closed system vaporizer; heated tobacco product
• Online Access: http://www.e-trd.org/upload/pdf/trd-2020-0150.pdf
• ISSN: 1738-3536; 2005-6184

Raising the tax on tobacco-related products is the most effective and sustainable intervention for smoking cessation. The 2015 tobacco-tax increase resulted in a decreased smoking rate among Korean adult men. However, participation in the government-sponsored smoking-cessation programs developed after the 2015 tobacco tax increase has declined sharply since 2018. The popularity of electronic cigarettes (e-cigarettes) seems to be an important factor in this decline. Indeed, the market share of e-cigarettes has increased steadily since 2007, when the e-cigarette was introduced in Korea as a vaporizer. The introduction of the tobacco-heating device IQOS in 2017 resulted in the skyrocketing popularity of e-cigarettes, especially among the young generation of Koreans. The U.S. Food and Drug Administration (FDA) authorized marketing of IQOS as a “reduced exposure” tobacco product on July 7, 2020, further complicating smoking-cessation efforts. The agency announced that IQOS produces fewer or lower levels of some toxins than combustible cigarettes. However, FDA authorization does not mean that these products are safe. There is no evidence that reducing the harmful chemical components leads to health benefits. Clinicians need to maintain the position that those who smoke, regardless of tobacco-product type, should be counseled for smoking cessation and prescribed appropriate proven pharmacologic agents.